CN106573985A - 抗vasa抗体及其生产方法和用途 - Google Patents

抗vasa抗体及其生产方法和用途 Download PDF

Info

Publication number
CN106573985A
CN106573985A CN201580045293.8A CN201580045293A CN106573985A CN 106573985 A CN106573985 A CN 106573985A CN 201580045293 A CN201580045293 A CN 201580045293A CN 106573985 A CN106573985 A CN 106573985A
Authority
CN
China
Prior art keywords
vasa
limited
cell
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580045293.8A
Other languages
English (en)
Chinese (zh)
Inventor
D·T·维沃
B·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ova Science Ltd By Share Ltd
Original Assignee
Ova Science Ltd By Share Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ova Science Ltd By Share Ltd filed Critical Ova Science Ltd By Share Ltd
Publication of CN106573985A publication Critical patent/CN106573985A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
    • C12Y306/04013—RNA helicase (3.6.4.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201580045293.8A 2014-09-16 2015-09-16 抗vasa抗体及其生产方法和用途 Pending CN106573985A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462051130P 2014-09-16 2014-09-16
US62/051,130 2014-09-16
US201462089054P 2014-12-08 2014-12-08
US62/089,054 2014-12-08
PCT/US2015/050449 WO2016044436A2 (en) 2014-09-16 2015-09-16 Anti-vasa antibodies, and methods of production and use thereof

Publications (1)

Publication Number Publication Date
CN106573985A true CN106573985A (zh) 2017-04-19

Family

ID=55454121

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580045293.8A Pending CN106573985A (zh) 2014-09-16 2015-09-16 抗vasa抗体及其生产方法和用途

Country Status (26)

Country Link
US (4) US9403913B2 (https=)
EP (1) EP3194448A4 (https=)
JP (2) JP2017532953A (https=)
KR (1) KR20170056521A (https=)
CN (1) CN106573985A (https=)
AP (1) AP2017009758A0 (https=)
AU (1) AU2015317813B2 (https=)
BR (1) BR112017003263A2 (https=)
CA (1) CA2959179A1 (https=)
CL (1) CL2017000402A1 (https=)
CO (1) CO2017001724A2 (https=)
CR (1) CR20170067A (https=)
DO (1) DOP2017000050A (https=)
EA (1) EA201790236A1 (https=)
EC (1) ECSP17011262A (https=)
GT (1) GT201700036A (https=)
IL (1) IL250451A0 (https=)
MX (1) MX358243B (https=)
NI (1) NI201700022A (https=)
PE (1) PE20170667A1 (https=)
PH (1) PH12017500309A1 (https=)
SG (1) SG11201701016WA (https=)
SV (1) SV2017005393A (https=)
TN (1) TN2017000066A1 (https=)
TW (1) TW201619194A (https=)
WO (1) WO2016044436A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025162029A1 (zh) * 2024-01-30 2025-08-07 抟相医药(杭州)有限公司 基于凝聚体荧光漂白恢复技术(Drop-FRAP)的生物大分子相互作用调节剂筛选平台

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint, Inc. Methods for treating Vascular Leak Syndrome and cancer
WO2016044436A2 (en) * 2014-09-16 2016-03-24 Ovascience, Inc. Anti-vasa antibodies, and methods of production and use thereof
AU2017299581B2 (en) 2016-07-20 2024-05-23 EyePoint, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-β)
CN120058958A (zh) 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
WO2020102565A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Systems and methods for nondestructive testing of gametes
US12534512B2 (en) 2019-11-11 2026-01-27 Vanderbilt University Human monoclonal antibodies to hantavirus and methods of use therefore

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036445A1 (en) * 1999-11-18 2001-05-25 The Brigham And Women's Hospital, Inc. Compositions and methods for the improved diagnosis and treatment of germ cell tumors
WO2013002880A1 (en) * 2011-06-29 2013-01-03 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039518A1 (en) * 1995-06-05 1996-12-12 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
US6875854B1 (en) * 1999-11-18 2005-04-05 The Brigham And Women's Hospital, Inc. Compositions and methods for the improved diagnosis and treatment of germ cell tumors
AU2005245899A1 (en) 2004-05-17 2005-12-01 The General Hospital Corporation Methods and compositions for producing germ cells from peripheral blood derived germline stem cells
US7955846B2 (en) 2004-05-17 2011-06-07 The General Hospital Corporation Compositions comprising female germline stem cells and methods of use thereof
CN1842540B (zh) * 2004-07-09 2012-07-04 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
EP1829961A4 (en) * 2004-12-22 2008-06-04 Chugai Pharmaceutical Co Ltd METHOD FOR THE PRODUCTION OF AN ANTIBODY USING A CELL WITH HARDENED FUCOSET TRANSPORT FUNCTION
EP2336311A4 (en) 2008-09-25 2012-07-04 Univ Tokyo Nat Univ Corp ANTIBODIES AGAINST TUNA VASA
CN102395603A (zh) * 2008-12-26 2012-03-28 国立大学法人东京大学 使用抗lgr7抗体的癌症的诊断和治疗
ES2624835T3 (es) * 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
EP3498826A1 (en) 2011-04-14 2019-06-19 The General Hospital Corporation Compositions and methods for autologous germline mitochondrial energy transfer
JP2016503817A (ja) * 2012-12-31 2016-02-08 ディヴェロップメント センター フォー バイオテクノロジー アンチグラニュリシン抗体及びその使用方法
WO2016044436A2 (en) * 2014-09-16 2016-03-24 Ovascience, Inc. Anti-vasa antibodies, and methods of production and use thereof
AU2016206945A1 (en) * 2015-01-13 2017-08-10 President And Fellows Of Harvard College Purification of germ stem cells by targeting MRP9

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036445A1 (en) * 1999-11-18 2001-05-25 The Brigham And Women's Hospital, Inc. Compositions and methods for the improved diagnosis and treatment of germ cell tumors
WO2013002880A1 (en) * 2011-06-29 2013-01-03 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025162029A1 (zh) * 2024-01-30 2025-08-07 抟相医药(杭州)有限公司 基于凝聚体荧光漂白恢复技术(Drop-FRAP)的生物大分子相互作用调节剂筛选平台

Also Published As

Publication number Publication date
EA201790236A1 (ru) 2017-11-30
GT201700036A (es) 2018-12-19
US20160311929A1 (en) 2016-10-27
WO2016044436A2 (en) 2016-03-24
JP2018148915A (ja) 2018-09-27
US9403913B2 (en) 2016-08-02
CL2017000402A1 (es) 2017-11-03
US20160075797A1 (en) 2016-03-17
TN2017000066A1 (en) 2018-07-04
PE20170667A1 (es) 2017-06-06
IL250451A0 (en) 2017-03-30
PH12017500309A1 (en) 2017-07-10
US20170107299A1 (en) 2017-04-20
CA2959179A1 (en) 2016-03-24
EP3194448A2 (en) 2017-07-26
MX2017002390A (es) 2017-07-28
TW201619194A (zh) 2016-06-01
WO2016044436A3 (en) 2016-06-09
AP2017009758A0 (en) 2017-02-28
MX358243B (es) 2018-08-10
DOP2017000050A (es) 2018-04-15
US20180155445A1 (en) 2018-06-07
NI201700022A (es) 2017-05-04
SG11201701016WA (en) 2017-03-30
AU2015317813B2 (en) 2018-04-05
CR20170067A (es) 2017-05-10
KR20170056521A (ko) 2017-05-23
CO2017001724A2 (es) 2017-07-19
EP3194448A4 (en) 2018-03-14
US9567404B2 (en) 2017-02-14
ECSP17011262A (es) 2017-05-31
SV2017005393A (es) 2017-06-07
BR112017003263A2 (pt) 2017-11-28
AU2015317813A1 (en) 2017-03-02
JP2017532953A (ja) 2017-11-09

Similar Documents

Publication Publication Date Title
US9567404B2 (en) Anti-vasa antibodies, and methods of production and use thereof
JP5522405B2 (ja) 安定な多価抗体
CN103429619B (zh) 双特异性和单特异性、不对称抗体和其制备方法
AU2014213147B2 (en) C5 antibody and method for preventing and treating complement-related diseases
WO2021058000A1 (zh) 抗人Claudin18.2抗体及其应用
JP7053479B2 (ja) ＩＬ７受容体細胞外ドメインα鎖に対する非拮抗性抗体及び癌治療におけるそれらの使用
CN113943366A (zh) 新型抗体框架
AU2017260232B2 (en) Anti-Kv1.3 antibodies, and methods of production and use thereof
WO2022267936A1 (zh) 特异性结合糖基化ceacam5的抗体
CN118946592A (zh) 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途
CA2964179C (en) Monoclonal anti-gpc-1 antibodies and uses thereof
CN118667003A (zh) 特异性结合Claudin18.2的抗体及其制法和应用
US12037409B2 (en) Antibody specifically bound to glycosylated CEACAM5
US20250163182A1 (en) Enpp3 and cd3 binding agents and methods of use thereof
JP7312834B2 (ja) 二価の二重特異性抗体およびその製造方法、コードする遺伝子、宿主細胞、組成物
WO2025086564A1 (zh) 抗人vsig4的抗体及其医药用途
HK1236552A1 (en) Anti-vasa antibodies, and methods of production and use thereof
OA18333A (en) Anti-Vasa antibodies, and methods of production and use thereof
CN111434686A (zh) 一种抗人pbx1单克隆抗体，其制备方法及其在复发性流产临床诊断中的用途
WO2025061149A1 (zh) 抗gcc抗体、嵌合抗原受体及其用途
US20260028399A1 (en) Human-like target-binding proteins
CN119409812A (zh) Icam-1抗体及其应用
CN114685656A (zh) 抗SIRPα单克隆抗体
WO2014006230A1 (en) Il-20 epitopes and il-20 ligands

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1236552

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170419

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1236552

Country of ref document: HK